Xeltis BV reported positive preliminary data from two ongoing clinical trials in Europe and South America evaluating its Xabg coronary artery bypass conduit. The device uses a novel polymer scaffold engineered with supramolecular chemistry to promote gradual replacement by a patient’s own tissue, restoring vascular function. Interim results show favorable safety and patency in patients with multi-vessel atherosclerotic disease, supporting continued development and potentially expanding options for synthetic vascular implants that regenerate living vessels.